Determination of the Affinity of Drugs toward Serum Albumin by Measurement of the Quenching of the Intrinsic Tryptophan Fluorescence of the Protein
Authors:
- 1 January 1999
- journal article
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 51 (1) , 41-48
Abstract
Binding of new chemical entities to serum proteins is an issue confronting pharmaceutical companies during development of potential therapeutic agents. Most drugs bind to the most abundant plasma protein, human serum albumin (HSA), at two major binding sites. Excepting fluorescence spectroscopy, existing methods for assaying drug binding to serum albumin are insensitive to higher-affinity compounds and can be labour-intensive, time-consuming, and usually require compound-specific assays. This led us to examine alternative ways to measure drug-albumin interaction. One method described here uses fluorescence quenching of the single tryptophan (Trp) residue in HSA excited at 295 nm to measure drug-binding affinity. Unfortunately, many compounds absorb, fluoresce, or both, in this UV wavelength region of the spectrum. Several types of binding phenomenon and spectral interference were identified by use of six structurally unrelated compounds and the equations necessary to make corrections mathematically were derived and applied to calculate binding constants accurately. The general cases were: direct quenching of Trp fluorescence by optically transparent ligands with low or high affinities; binding of optically transparent, non-fluorescent ligands to two specific sites where both sites or only one site result in Trp fluorescence quenching; and chromophores whose absorption either overlaps the Trp emission and quenches by energy transfer or absorbs light at the Trp fluorescence excitation wavelength producing absorptive screening as well as fluorescence quenching. Unless identification of the site specificity of drug binding to serum albumin is desired, quenching of the Trp fluorescence of albumin by titration with ligand is a rapid and facile method for determining the binding affinities of drugs for serum albumin.Keywords
This publication has 10 references indexed in Scilit:
- Drug-protein binding studies new trends in analytical and experimental methodologyJournal of Chromatography B: Biomedical Sciences and Applications, 1996
- Chapter 33. Plasma Protein Binding of Drugs1996
- A General, Wide-Range Spectrofluorometric Method for Measuring the Site-Specific Affinities of Drugs Toward Human Serum AlbuminAnalytical Biochemistry, 1995
- Drug Binding in PlasmaClinical Pharmacokinetics, 1994
- Atomic structure and chemistry of human serum albuminNature, 1992
- Effects of drug bindings on the esterase-like activity of human serum albumin. VII. Subdivision of R-type drugs inhibiting the activity towards p-nitrophenyl acetate.Chemical and Pharmaceutical Bulletin, 1987
- Effects of drug binding on the esterase activity of human serum albumin: Inhibition modes and binding sites of anionic drugs.Chemical and Pharmaceutical Bulletin, 1980
- Phenylbutazone–Sodium Warfarin Binding Using a Fluorescent Probe TechniqueJournal of Pharmaceutical Sciences, 1972
- Binding Study of p-Hydroxybenzoic Acid Esters to Bovine Serum Albumin by Fluorescent Probe TechniqueJournal of Pharmaceutical Sciences, 1971
- Steroid-protein interactions studied by fluorescence quenchingBiochimica et Biophysica Acta (BBA) - Protein Structure, 1968